MiNK Therapeutics — Third Quarter 2026 Earnings Summary

MiNK Therapeutics reported its first pre-commercial product revenue in the third quarter of 2026 from agenT-797 supplied via an international named-patient access program. The company's randomized Phase 2 trial for acute respiratory distress syndrome (ARDS) is advancing with U.S. dosing expected before year-end, targeting a population with approximately 40% 28-day mortality. Additionally, agenT-797 was selected for the ARPA-H BoSS program to develop room-temperature deployable cell therapies, while preclinical data presented at SITC 2026 demonstrated the therapy's ability to clear senescent cells and enhance tumor killing in colorectal cancer models. Financially, the company achieved a 23% year-over-year improvement in net loss per share and reduced general and administrative expenses by 44%.